Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives $34.86 Average Price Target from Analysts

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOKGet Rating) have been assigned a consensus recommendation of “Buy” from the six analysts that are currently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have covered the stock in the last year is $33.83.

A number of research analysts recently commented on STOK shares. Cantor Fitzgerald lowered their price objective on shares of Stoke Therapeutics from $38.00 to $20.00 in a research note on Tuesday, November 15th. SVB Leerink upgraded shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating and set a $30.00 price target on the stock in a research report on Monday, October 24th. Credit Suisse Group decreased their price target on shares of Stoke Therapeutics from $50.00 to $38.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 15th. Finally, Needham & Company LLC decreased their price target on shares of Stoke Therapeutics from $50.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, November 14th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Teachers Retirement System of The State of Kentucky bought a new position in shares of Stoke Therapeutics during the 3rd quarter worth about $547,000. Balyasny Asset Management LLC acquired a new stake in shares of Stoke Therapeutics during the 3rd quarter valued at about $147,000. Jane Street Group LLC acquired a new stake in shares of Stoke Therapeutics during the 3rd quarter valued at about $222,000. BNP Paribas Arbitrage SNC boosted its position in shares of Stoke Therapeutics by 19.0% during the 3rd quarter. BNP Paribas Arbitrage SNC now owns 17,112 shares of the company’s stock valued at $220,000 after acquiring an additional 2,736 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of Stoke Therapeutics by 16.0% during the 3rd quarter. Alliancebernstein L.P. now owns 27,500 shares of the company’s stock valued at $353,000 after acquiring an additional 3,800 shares in the last quarter.

Stoke Therapeutics Trading Down 1.8 %

NASDAQ STOK opened at $7.67 on Friday. Stoke Therapeutics has a 12 month low of $7.17 and a 12 month high of $28.54. The company’s 50 day simple moving average is $12.53 and its 200 day simple moving average is $13.99.

Stoke Therapeutics Company Profile

(Get Rating)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.

Featured Articles

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.